Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more.
BMJ Oncol
October 2024
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Clinical endpoints, such as overall survival, directly measure relevant outcomes. Surrogate endpoints, in contrast, are intermediate, stand-in measures of various tumour-related metrics and include tumour growth, tumour shrinkage, blood results, etc. Surrogates may be a time point measurement, that is, tumour shrinkage at some point (eg, response rate) or biomarker-assessed disease status, measured at given time points (eg, circulating tumour DNA, ctDNA).
View Article and Find Full Text PDFBackground: Anti-CD38 monoclonal antibodies (mAbs) have significantly changed the multiple myeloma treatment landscape. This meta-analysis compared the efficacy and safety of anti-CD38 mAb-based therapy versus standard therapy in newly diagnosed multiple myeloma (NDMM) patients.
Methods: We performed a comprehensive literature search on PubMed, the Cochrane Database, and ClinicalTrials.
Prognostic Value of Dynamic Measurable Residual Disease Monitoring by Multiflowcytometry in Elderly Patients With Nonintensively Treated Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk
January 2025
Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. Electronic address:
Purpose: The clinical prognostic value of monitoring minimal residual disease (MRD) in acute myeloid leukemia (AML) patients undergoing nonintensive treatment remains insufficiently established. The aim of this work was to examine MRD status at various time points, highlighting the potential for pre-emptive therapy to improve patient outcomes.
Methods: Inpatient data from 2017 to 2024 were used in this retrospective study.
Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment.
Genes (Basel)
January 2025
IFOM-The AIRC Institute of Molecular Oncology, 20139 Milano, Italy.
This review provides a comprehensive overview of the evolving role of minimal residual disease (MRD) for patients with Colon Cancer (CC). Currently, the standard of care for patients with non-metastatic CC is adjuvant chemotherapy (ACT) for all patients with stage III and high-risk stage II CC following surgical intervention. Despite a 5-20% improvement in long-term survival outcomes, this approach also results in a significant proportion of patients receiving ACT without any therapeutic benefit and being unnecessarily exposed to the risks of secondary side effects.
View Article and Find Full Text PDFApplication of TRIM58 Gene Methylation-Based Minimal Residual Disease Assays in Non-Small Cell Lung Cancer for Prognosis Prediction and Treatment Decision.
Ann Clin Lab Sci
November 2024
Department of Thoracic Surgery, First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Objective: To identify key genes associated with the prognosis of non-small cell lung cancer (NSCLC) through bioinformatics analysis and experimental validation, exploring the expression of the TRIM58 gene and its potential effect as a tumor suppressor.
Methods: In this study, differentially expressed genes (DEGs) and differentially methylated genes (DMGs) related to lung adenocarcinoma and lung squamous cell carcinoma were selected from the TCGA dataset, with the Limma package in R software used for further filtering and intersection, followed by the assessment of the relationship between these genes and NSCLC prognosis using log-rank tests and univariate Cox regression analysis. Meanwhile, six clinical NSCLC cancer and adjacent tissue samples were collected, along with the detection of TRIM58 mRNA and protein levels using RT-PCR and Western blot.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!